Patents Assigned to Delenex Therapeutics AG
  • Antibody to human IL-1 beta
    Patent number: 9404930
    Abstract: The present invention relates to anti-IL-1 beta binding members and in particular to monovalent high potency IL-1 beta-binding antibody fragments being highly stable and soluble. Such binding members may be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: August 2, 2016
    Assignee: DELENEX THERAPEUTICS AG
    Inventors: Stefanie Grabulovski, Titus Kretzschmar, Simone Schmitt, Abdijapar Shamshiev, Thorsten Alexander Schäfer
  • Humanized antibodies against the beta-amyloid peptide
    Patent number: 9273126
    Abstract: The invention discloses an isolated antibody that selectively binds to the C-terminal part of Abeta and is humanized or fully human. The antibody of the invention is capable of preventing oligomerization of Abeta. Furthermore, a method of diagnosis comprising the steps of: (i) Labelling an antibody; (ii) Administering an effective dose of said antibody intranasally or systemically to a subject; and (iii) Detecting the concentration and/or presence of the labelled antibody in body parts of the subject is disclosed.
    Type: Grant
    Filed: November 2, 2012
    Date of Patent: March 1, 2016
    Assignees: Delenex Therapeutics AG, University of Zurich
    Inventors: Stefan Ewert, Adrian Auf Der Maur, Susann Cattepoel, Roger Nitsch
  • Method for treating glioblastoma using antibodies binding to the extracellular domain of the receptor tyrosine kinase ALK
    Patent number: 8945563
    Abstract: The present invention concerns an antibody specific for human ALK (Anaplastic Lymphoma Kinase), in particular a scFv, a nucleic acid sequence encoding it, its production and its use as a pharmaceutical or for diagnostic purposes. Said antibody is suitable for the local treatment of tumors, in particular glioblastoma.
    Type: Grant
    Filed: January 31, 2011
    Date of Patent: February 3, 2015
    Assignee: Delenex Therapeutics AG
    Inventors: Adrian Auf Der Maur, Alcide Barberis, Peter Lichtlen
  • BINDING MEMBERS TO IL-1 BETA
    Publication number: 20140134183
    Abstract: The present invention relates to anti-IL-1 beta binding members and in particular to monovalent high potency IL-1 beta-binding antibody fragments being highly stable and soluble. Such binding members may be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.
    Type: Application
    Filed: November 5, 2013
    Publication date: May 15, 2014
    Applicant: Delenex Therapeutics AG
    Inventors: Stefanie Grabulovski, Titus Kretzschmar, Simone Schmitt, Abdijapar Shamshiev
  • Humanized antibodies against the ?-amyloid peptide
    Patent number: 8323647
    Abstract: The invention discloses an isolated antibody that selectively binds to the C-terminal part of Abeta and is humanized or fully human. The antibody of the invention is capable of preventing oligomerization of Abeta. Furthermore, a method of diagnosis comprising the steps of: (i) Labelling an antibody; (ii) Administering an effective dose of said antibody intranasally or systemically to a subject; and (iii) Detecting the concentration and/or presence of the labelled antibody in body parts of the subject is disclosed.
    Type: Grant
    Filed: September 15, 2008
    Date of Patent: December 4, 2012
    Assignees: Delenex Therapeutics AG, University of Zurich
    Inventors: Stefan Ewert, Adrian Auf Der Maur, Susann Cattepoel, Roger Nitsch
  • Antibodies Binding To The Extracellular Domain Of The Receptor Tyrosine Kinase ALK
    Publication number: 20110159008
    Abstract: The present invention concerns an antibody specific for human ALK (Anaplastic Lymphoma Kinase), in particular a scFv, a nucleic acid sequence encoding it, its production and its use as a pharmaceutical or for diagnostic purposes. Said antibody is suitable for the local treatment of tumors, in particular glioblastoma.
    Type: Application
    Filed: January 31, 2011
    Publication date: June 30, 2011
    Applicant: DELENEX THERAPEUTICS AG
    Inventors: Adrian Auf Der Maur, Alcide Barberis, Peter Lichtlen
  • Antibodies binding to the extracellular domain of the receptor tyrosine kinase ALK
    Patent number: 7902340
    Abstract: The present invention concerns an antibody specific for human ALK (Anaplastic Lymphoma Kinase), in particular a scFv, a nucleic acid sequence encoding it, its production and its use as a pharmaceutical or for diagnostic purposes. Said antibody is suitable for the local treatment of tumors, in particular glioblastoma.
    Type: Grant
    Filed: April 27, 2007
    Date of Patent: March 8, 2011
    Assignee: Delenex Therapeutics AG
    Inventors: Adrian Auf Der Maur, Alcide Barberis, Peter Lichtlen
  • HUMANIZED ANTIBODIES AGAINST THE BETA-AMYLOID PEPTIDE
    Publication number: 20110020220
    Abstract: The invention discloses an isolated antibody that selectively binds to the C-terminal part of Abeta and is humanized or fully human. The antibody of the invention is capable of preventing oligomerisation of Abeta. Furthermore, a method of diagnosis comprising the steps of: (i) Labelling an antibody; (ii) Administering an effective dose of said antibody intranasally or systemically to a subject; and (iii) Detecting the concentration and/or presence of the labelled antibody in body parts of the subject is disclosed.
    Type: Application
    Filed: September 15, 2008
    Publication date: January 27, 2011
    Applicants: Delenex Therapeutics AG, University of Zurich Prorektorat Forschung
    Inventors: Stefan Ewert, Adrian Auf Der Maur, Susann Cattepoel, Roger Nitsch
  • ANTIGEN-BINDING POLYPEPTIDES AGAINST CARTILAGE DEGENERATION
    Publication number: 20110002927
    Abstract: The invention provides an antigen-binding polypeptide which is able to penetrate into the cartilage. The disclosed polypeptide, compositions and methods are suitable for the treatment, prevention and/or delay of progression of cartilage degeneration.
    Type: Application
    Filed: February 5, 2009
    Publication date: January 6, 2011
    Applicant: Delenex Therapeutics AG
    Inventors: David M Urech, Peter Lichtlen